A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes

Eric Huselton,Michael P. Rettig,Theresa Fletcher,Julie Ritchey,Leah Gehrs,Kyle McFarland,Stephanie Christ,William C. Eades,Kathryn Trinkaus,Rizwan Romee,Shashikant Kulkarni,Armin Ghobadi,Camille N. Abboud,Amanda F. Cashen,Keith Stockerl-Goldstein,Geoffrey L. Uy,Ravi Vij,Peter Westervelt,John F. DiPersio,Mark A. Schroeder

A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes

2021

Interactions between the bone marrow microenvironment and MDS tumor clones play a role in pathogenesis and response to treatment. We hypothesized G-CSF and plerixafor may enhance sensitivity to aza...

Keywords:

Internal medicine
Regimen
dose limiting toxicity
Oncology
Myelodysplastic syndromes
Plerixafor
Medicine
in patient
Azacitidine
Leukocytosis
Bone marrow

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations